Aquestive Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Aquestive Therapeutics

29/10/2022 03:03

* Aquestive Therapeutics Inc  AQST.OQ   AQST.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 1. 
    * The Warren New Jersey-based  company is expected to report
 a
16.9% decrease in revenue to $11.038 million from $13.29 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aquestive
Therapeutics
Inc is for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aquestive
Therapeutics Inc is $6​, above​ its last closing price of $0.86.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.36       -0.36      -0.36     Met     0
 Mar. 31 2022  -0.39       -0.41      -0.32     Beat    21.6
 Dec. 31 2021  -0.42       -0.47      -0.38     Beat    18.7​
 Sep. 30 2021  -0.43       -0.45      -0.37     Beat    17.8
 ​​Jun.        -0.44       -0.44      -0.33     Beat    24.7
 30 2021                                                
 Mar. 31 2021  -0.43       -0.43      -0.41     Beat    3.8​
 Dec. 31 2020  -0.49       -0.26      -0.60     Missed  -130.8
 Sep. 30 2020  -0.46       -0.46      -0.49     Missed  -7.5
 This summary was machine generated October 29 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated